Lenalidomide Arrow (Lenalidomide)

Lenalidomide binds to cereblon, a component of the CRL4 E3 ubiquitin ligase complex, altering its substrate specificity. This triggers ubiquitination and proteasomal degradation of transcription factors Ikaros and Aiolos, leading to immune modulation, inhibition of angiogenesis, and direct anti‑tumor effects in malignant plasma cells.

The dose of Lenalidomide Arrow is individualized by the prescribing clinician based on the specific indication, disease stage, renal function, and patient tolerance. No universal dosing schedule is provided here; the prescriber will calculate the appropriate regimen according to current clinical guidelines and patient characteristics.

Lenalidomide is classified as Pregnancy Category X because it is teratogenic and can cause fetal harm. It is contraindicated in pregnant women and should not be used by women who are or may become pregnant without effective contraception. Breastfeeding is also not recommended while receiving lenalidomide.

To place an order, submit an enquiry on the Lenalidomide Arrow product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Both lenalidomide and thalidomide belong to the immunomodulatory imide drug (IMiD) class, but lenalidomide is generally more potent, has a more favorable safety profile, and exhibits less peripheral neuropathy. Clinical trials have shown higher response rates in multiple myeloma for lenalidomide, while thalidomide remains an option when lenalidomide is not suitable.

Lenalidomide Arrow should be stored at ambient temperature, ideally below 25 °C (77 °F). Keep the product in its original packaging, protect it from moisture and direct light, and avoid storing it in areas with high humidity or temperature fluctuations to maintain potency.

Lenalidomide Arrow is taken orally, usually as a whole tablet swallowed with water. It can be taken with or without food, but patients should follow the specific instructions provided by their healthcare professional regarding timing and any dietary considerations.

The most serious risks include thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, severe neutropenia that can predispose to infections, secondary primary malignancies, and teratogenic effects that can cause birth defects. Patients should be monitored closely for signs of these complications.

Lenalidomide Arrow should not be used by pregnant women, individuals with known hypersensitivity to lenalidomide or any component of the formulation, patients with uncontrolled infections, or those for whom the risk–benefit assessment is unfavorable. Clinicians must also consider contraindications related to severe renal impairment or concurrent use of certain interacting drugs.